Review article: Pathogenesis and pathophysiology of hepatorenal syndrome - Is there scope for prevention?

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue SUPPL. 3, 2004, Pages 31-41

  Moller S ^a,b   Henriksen, J H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANRENONE; CAPTOPRIL; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; HUMAN ALBUMIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIXIVAPTAN; LOSARTAN; NORADRENALIN; PLASMA SUBSTITUTE; PROSTAGLANDIN E2; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST;

ADRENERGIC SYSTEM; ASCITES; BLEEDING; CHRONIC LIVER DISEASE; CONFERENCE PAPER; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; HYPOTENSION; HYPOVOLEMIA; INFECTION; KIDNEY BLOOD FLOW; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PATHOGENESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RETENTION; SPLANCHNIC BLOOD FLOW; TISSUE PRESSURE; VASOCONSTRICTION; VASODILATATION; WATER RETENTION;

EID: 4644288294     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02112.x     Document Type: Conference Paper

References (87)

1. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32: 141-56.
2. Henriksen JH. Cirrhosis: Ascites and hepatorenal syndrome. Recent advances in pathogenesis. J Hepatol 1995; 23: 25-30.
3. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362: 1819-27.
4. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis. A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 5: 1151-7.
5. Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-70.
6. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.
7. Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood Volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 90-4.
8. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis. Pathogenesis and Treatment. Gastroenterology 2002; 122: 1658-76.
9. Cassinello C, Moreno E, Gozalo A, Ortuno B, Cuenca B, Solis-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 2003; 48: 179-86.
10. Kostreva DR, Pontus SP. Hepatic vein, hepatic parenchymal, and inferior vena caval mechanoreceptors with phrenic afferents. Am J Physiol 1993; 28: G15-20.
11. Levy M, Wexler MJ. Hepatic denervation alters first-phase urinary sodium excretion in dogs with cirrhosis. Am J Physiol 1987; 253: F664-71.
12. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes EC. Reduction in renal blood flow following acute increase in the portal pressure. Evidence for the existence of a hepatorenal reflex in man? Gut 1997; 40: 664-70.
13. Jalan R, Hayes PC. Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure. Gut 2000; 46: 527-33.
14. Kapoor D, Redhead DN, Hayes PC, Webb DJ, Jalan R. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl 2003; 9: 32-9.
15. Ming Z, Smyth DD, Lautt WW. Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: role of adenosine. Hepatology 2002; 35: 167-75.
16. Llach J, Ginés P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
17. Møller S. Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis. Dan Med Bull 1998; 45: 1-14.
18. Bernardi M, Fornale L, Dimarco C, et al. Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol 1995; 22: 309-18.
19. Gentilini P, Romanelli RG, Laffi G, et al. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. J Hepatol 1999; 30: 632-8.
20. Henriksen JH, Bendtsen F, Gerbes AL, Christensen NJ, Ring-Larsen H, Sørensen TIA. Estimated central blood volume in cirrhosis - relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16: 1163-70.
21. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann RJ, eds. Portal Hypertension. Pathophysiology and Treatment. Oxford: Blackwell, 1994: 17-26.
22. Martin PY, Gines P, Schrier RW. Mechanisms of disease: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-41.
23. Møller S, Bendtsen F, Schifter S, Henriksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. Scand J Gastroenterol 1996; 31: 928-33.
24. Guevara M, Gines P, Jimenez W, Sort P, et al. Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114: 336-43.
25. Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-32.
26. Lee FY, Lin HC, Tsai YT, et al. Plasma substance P levels in patients with liver cirrhosis: relationship to systemic and portal hemodynamics. Am J Gastroenterol 1997; 92: 2080-4.
27. Møller S, Henriksen JH. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998; 58: 361-72.
28. Møller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001; 61: 421-9.
29. Fernandez-Varo G, Ros J, et al. Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol 2003; 162: 1985-93.
30. Møller S, Wünberg N, Henriksen JH. Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology 1995; 22: 88-95.
31. Nicholls KM, Shapiro MD, Kluge R. Sodium excretion in advanced cirrhosis: Effect of expansion of central blood volume and suppression of plasma aldosterone. Hepatology 1986; 82: 709-19.
32. Lenz K, Hörtnagel H, Druml W, et al. Ornipressin in the treatment of functional renal failure in decompensated cirrhosis: effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991; 101: 1060-7.
33. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma Volume expansion. Hepatology 1998; 27: 35-41.
34. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.
35. Bernardi M, Dimarco C, Trevisani F, et al. Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 1993; 105: 188-93.
36. Henriksen JH, Gótze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis, relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52: 1511-7.
37. Kiil F. The mechanism of renal autoregulation. Scand J Clin Lab Invest 1981; 41: 521-5.
38. Cowley AW Jr. Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol 1997; 273: R1-15.
39. Holdaas H, Langaard O, Eide I, Kiil F. Conditions for enhancement of renin release by isoproterenol, dopamine, and glucagon. Am J Physiol 1982; 242: F267-73.
40. Llach J, Gines P, Arroyo V, et al. Effect of dipyridamole on kidney function in cirrhosis. Hepatology 1993; 17: 59-64.
41. Forrest EH, Bouchier IAD, Hayes PC. Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis. Gut 1997; 40: 139-44.
42. Ma Z, Lee SS. Cirrhotic cardiomyopathy: Getting to the heart of the matter. Hepatology 1996; 24: 451-9.
43. Ruiz-Del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-8.
44. Gerbes AL, Gülberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933-9.
45. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders. Role of the renin-angiotensin-aldosterone system. Sem Liver Dis 1994; 14: 23-34.
46. Arroyo V, Jimenez W. Clinical need for antidiuretic hormone antagonists in cirrhosis. Hepatology 2003; 37: 13-5.
47. Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 1990; 11: 153-8.
48. Rimola A, Gines P, Arroyo V. Urinary excretion of 6-keto-PGF-1-alpha, thromboxane B-2 and prostaglandin E-2 in cirrhosis with ascites: Relationship to functional renal failure (hepatorenal syndrome). J Hepatol 1986; 3: 111-7.
49. Ros J, Claria J, Jimenez W, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995; 22: 915-20.
50. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114: 344-51.
51. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-8.
52. Floras JS, Legault L, Morali GA, Kara K, Blendis LM. Increased sympathetic outflow in cirrhosis and ascites: Direct evidence from intraneural recordings. Ann Int Med 1991; 114: 373-80.
53. Henriksen JH, Møller S. Hemodynamics, distribution of blood volume, and kinetics of vasoactive substances in cirrhosis. In: Epstein, M, ed. The Kidney in Liver Disease. Philadelphia: Hanley and Belfus, 1996, 241-58.
54. Vlachogiannakos J, Tang AKW, Patch D, Burroughs AK. Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001; 49: 303-8.
55. Fernandez Llama P, Turner R, Dibona G, Knepper MA. Renal expression of aquaporins in liver cirrhosis induced by chronic common bile duct ligation in rats. J Am Soc Nephrol 1999; 10: 1950-7.
56. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36: 1197-205.
57. Møller S, Henriksen JH. Endothelins in chronic liver disease. Scand J Clin Lab Invest 1996; 56: 481-90.
58. Bernardi M, Gülberg V, Colantoni A, Trevisani F, Gasbarrini A, Gerbes AL. Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol 1996; 24: 161-8.
59. Trevisani F, Colantoni A, Gerbes AL, et al. Daily profile of plasma endothelin-1 and -3 in pre-ascitic cirrhosis: Relationships with the arterial pressure and renal function. J Hepatol 1997; 26: 808-15.
60. Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996; 347: 1842-3.
61. Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am J Gastroenterol 2002; 97: 707-13.
62. Trevisani F, Sica G, Mainqua P, et al. Autonomie dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 1999; 30: 1387-92.
63. Laffi G, Barletta G, Lavilla G, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113: 891-8.
64. LaVilla G, Barletta G, Romanelli RG, et al. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology 2002; 35: 1441-8.
65. MacGilchrist AJ, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: Evidence for a peripheral vascular defect. Hepatology 1991; 13: 689-94.
66. Ryan J, Sudhir K, Jennings G, Esler M, Dudley F. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993; 105: 1167-72.
67. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15.
68. Møller S, Søndergaard L, Møgelvang J, Henriksen O, Henriksen JH. Decreased right heart blood Volume determined by magnetic resonance imaging: Evidence of central underfilling in cirrhosis. Hepatology 1995; 22: 472-8.
69. Finucci G, Desideri A, Sacerdoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996; 31: 279-84.
70. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rôssle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999; 44: 743-8.
71. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-22.
72. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-95.
73. Salerno F, Cazzaniga M, Pagnozzi G, et al. Humoral and cardiac effects of TIPS in cirrhotic patients with different 'effective' blood volume. Hepatology 2003; 38: 1370-7.
74. Gadano A, Moreau R, Vachiery F, et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997; 26: 1229-34.
75. Therapondos G, Stanley AJ, Hayes PC. Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: Pilot study. J Gastroenterol Hepatol 2004; 19: 73-7.
76. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000; 20: 51-9.
77. Mulkay JP, Louis H, Donckier V, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64: 15-9.
78. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
79. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-6.
80. Brinch K, Møller S, Bendtsen F, Becker U, Henriksen JH. Plasma Volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003; 39: 24-31.
81. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.
82. Gines P, De Guevara M, Las HD, Arroyo V. Review article: albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16 (Suppl. 5): 24-31.
83. Ruiz-Del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.
84. Folio A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-501.
85. Fernandez J, Navasa M, Garcia-Pagan JC, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal sytems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2004; in press.
86. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-48.
87. Gines A, Salmeron JM, Gines P, et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993; 17: 220-6.